Abstract
Background:
Chromium and its salts, as well as chromium-containing compounds, play a major role in numerous manufacturing processes and have been contraindicated in carcinogenic, toxic, and mutagenic conditions in people involved in these processes.Objectives:
This study investigated the ameliorative role of Acacia nilotica aqueous leave extract (ANLA) on potassium dichromate-induced liver and blood toxicity in male and female rats. Phytochemical screening and nutrient composition of ANLA were also evaluated.Methods:
Phytochemical and proximate analysis of ANLA were carried out. Twenty adult male and female rats each were divided into four groups (n = 10): (1) control; (2) potassium dichromate (PDC; 0.625 mg/kg body weight); (3) PDC co-treated with ANLA after seven days (650 mg/kg bwt); and (4) PDC co-treated with ANLA (650 mg/kg bwt) simultaneously for 21 days. Biomarkers of liver injury, lipid, and hematological imbalance were assessed. Tissue histology and toxicant retention were done.Results:
Various plant secondary metabolites (flavonoids, terpenoids, tannins, phenols, saponins, cardiac glycosides, alkaloids, and anthraquinones) and nutrients (protein = 67.41 ± 2.44%; carbohydrate = 9.87 ± 1.87%; fiber = 10.01 ± 1.21%; mineral = 6.41 ± 1.08%; fat and oil = 6.63 ± 0.93%) were identified in the leave. Exposure to chromium significantly (P < 0.05) increased plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) with a concomitant decrease in the activity of these enzymes in the liver of both male and female rats. The exposure also altered protein, triglyceride, and cholesterol levels in the plasma and liver as well as hematological indices. Organ chromium retention and pathological changes were also observed. ANLA modulated these chromium-induced alterations in the rats.Conclusions:
Based on the results, ANLA possesses ameliorative property against PDC-induced toxicity in rats. Thus it may be used to combat chromium poisoning. The nutritive potential of A. nilotica leaves may also be maximized.Keywords
Liver Injury Chromium-Induced Toxicity Lipid Imbalance Chromium Poisoning Hematotoxicity Nutritive Composition Acacia nilotica
1. Background
Metals as environmental and occupational toxicants, are a major source of concern due to their long-term contraindication in the development of adverse health conditions. Cadmium, nickel, chromium, to mention a few are vastly distributed metals, potentially giving rise to environmental and occupational exposure risks, which may have deleterious effects on human health (1). These metals are of great concern as a result of their non-biodegradable properties, which contribute to their tendency to accumulate in living organisms causing detrimental diseased conditions (2). Chromium and its salts, as well as chromium-containing compounds, play a major role in numerous manufacturing processes and have been contraindicated in carcinogenic, toxic, and mutagenic conditions in people involved in these processes (3, 4). Hexavalent chromium [Cr (VI)] is one of the valence state chromium majorly exists in the environment. It is found on surface coatings and in water systems under alkaline pH and mild oxidizing conditions posing a major environmental health challenge (5). It easily permeates the cell membrane with the aid of the sulphate anion transport system present in the membrane and thereafter reduced to other lower oxidation states, leading to accumulation in various organs and triggering a multiplex of reactive oxygen species (ROS) and organ damage (6-8).
Acacia nilotica (L.), commonly known as "Babool wood" or "Babul" is found in different parts of South Asia, and Africa belongs to the Fabaceae family and Mimosoideae subfamily (9). In these parts of the world where they are found, they are used as both medicinal and ornamental plants by the locals. Its ethnopharmacological applications include treatment of congestion, diarrhea, sclerosis, bleeding piles, coughs, diabetes, hemorrhages, dysentery, bronchitis, and fever. It is also used to treat oral, bone, and skin-related diseases by the locals by preparation of infusions and decoctions (9-11). A. nilotica plant parts are made up of rich and diverse phytocompounds such as ellagic acid, leucocyanidin, galloylated catechins, (+)-catechin, 5,7-digallateumbelliferone, γ-sitosterol, niloticane, catechin, kaempferol, rutin, apigenin, and others (10, 12). They have also been reported to exhibit antimutagenic, hepatoprotective, antimicrobial, antidiabetic, anticancer, nephroprotective, anti-inflammatory, anti-Alzheimer’s and antioxidative activities (13-15). Various researchers have also reported the adsorbent property of A. nilotica bark in removing hexavalent chromium from aqueous solutions (16, 17). Based on these studies, we hypothesized the adsorbent potential of A. nilotica leaves in animals preventing Cr (VI) accumulation and related systemic damage. To investigate this hypothesis, this study aimed to investigate the ameliorative role of A. nilotica aqueous leave extract on potassium dichromate-induced hepato- and hemotoxicity in male and female rats. Phytochemical screening and nutritive composition of the extract was also assessed.
2. Methods
2.1. Chemical and Reagents
Potassium dichromate (K2Cr2O7) (PDC) was procured from Guangdong Guanghua SciTech Co., Ltd in Shantou, Guangdong, China, while perchloric acid, sulphuric acid, and trioxonitrate (IV) acid were procured from Sigma Chemical Company, Germany. Biochemical kits were gotten from Randox Ltd, UK. All other chemicals were products of Merck, Germany, and were of analytical grade.
2.2. Plant Collection, Identification, and Extraction
A. nilotica leaves were gotten from Birnin Kebbi, Kebbi State, identified by Dr. J. O. Popoola, and voucher specimen deposited at the herbarium of the University of Lagos with voucher number LUH 7553. Aqueous leaf (ANLA) extract was prepared as described by Iheagwam, Nsedu (18) with slight modification. Briefly, leaves were washed, air-dried under room temperature, and pulverized. Powder was macerated in distilled water by preparing a 10% (w/v) solution for 72 h with frequent gentle agitation before the filtrate was freeze-dried.
2.3. Phytochemical and Proximate Analysis
Qualitative phytochemical and proximate analysis were carried out according to standard methods as described by Iheagwam, Nsedu (18), and Elizabeth, Nonso (19), respectively.
2.4. Experimental Animals and Setup
Albino rats (n = 40; male = 20, female = 20) weighing between 180 - 200 g were purchased from the Estratop farm, Ifoyintedo, Ogun state. The animals were housed in the animal unit of the Department of Biochemistry, Covenant University, and maintained under standard conditions with the provision of feed and water ad libitum. All animal-handling methods were in compliance with the guidelines for the care and use of lab animals documented by the National Institute of Health. Approval was granted by the Biological Sciences Research Ethics Committee. Two weeks after acclimatization, the animals were divided into four groups of five rats each: (1) group 1 (Ctrl) was administered water and served as the control (n = 10; male = 5, female = 5); (2) group 2 (Cr) received potassium dichromate (PDC; K2Cr2O7; 0.635 mg/kg body weight) dissolved in distilled water by oral gavage (n = 10; male = 5, female = 5); (3) group 3 (Cr + A*) received PDC after seven days were co-treated with ANLA (650 mg/kg bwt) (n = 10; male = 5, female = 5); (4) group 4 (Cr + A) received PDC co-treated with ANLA (Cr + A) simultaneously (n = 10; male = 5, female = 5).
The experimental duration was 21 days. After that, rats were fasted on the last day for 12 h and sacrificed through cardiac puncture under mild euthanasia using diethyl ether.
2.5. Sample Collection
During the sacrifice, blood was collected into EDTA and heparin tubes for hematological and biochemical assays, respectively, while liver tissue was collected, cleaned, and placed in a homogenizing buffer (0.25 M sucrose solution). Liver tissue was collected, cleaned, and fixed in a 10% formalin solution for histological studies, while, liver, heart, intestine, spleen, kidney, muscle, and testis were digested and prepared for chromium concentration analysis.
2.6. Sample Preparation
Blood samples from the heparin tube were centrifuged at 2,000 g for 5 min, while liver tissues in 0.25 M sucrose solution were homogenized and centrifuged at 5,000 g for 10 min. The supernatants (plasma and liver homogenate, respectively) were collected into sterile tubes and stored at -20°C until they were required for biochemical analysis.
2.7. Biochemical Analysis and Histology
Plasma and liver alanine aminotransferase, aspartate aminotransferase, cholesterol, and triglyceride levels were carried out using Randox test kits, while protein concentration was assayed according to the method of Lowry and colleagues (20). Liver histology observation using hematoxylin and eosin staining as well as bioaccumulation of chromium in tissues were carried out according to the methods described by Kumari and colleagues (21).
2.8. Statistical Analysis
Statistical analysis was done by one-way analysis of variance (ANOVA) with Duncan post hoc at P < 0.05 significant level using IBM Statistical Package for Social Scientists (SPSS). All experimental data were expressed as mean ± standard error of the mean (SEM) of five replicates.
3. Results
The results of phytochemical screening revealed the presence of flavonoids, terpenoids, saponins, cardiac glycoside, tannins, alkaloids, phenol, and anthraquinone in A. nilotica aqueous leaf extract (Table 1). Results, as presented in Table 2, showed the nutritive component of the crude extract was made up of plant and animal protein (67.41 ± 2.44%), carbohydrate (9.87 ± 1.87%), fiber (10.01 ± 1.21%), fat, and oil (6.63 ± 0.93%) and lastly mineral (6.41 ± 1.08%) being the least. Daily intake of PDC increased (P < 0.05) the activities of AST and ALT in the plasma whilst reducing (P < 0.05) their activity in the liver compared with the control. Oral administration of ANLA reduced (P < 0.05) the activities of plasma AST and ALT to normal and near-normal levels, respectively, while liver AST and ALT activities were increased (P < 0.05) to near-normal levels when compared with the Cr group (Figures 1 and 2). On the other hand, PDC did not have any observable effect (P > 0.05) on male rats' plasma protein concentration; however, it reduced (P < 0.05) that of the female rats while increasing (P < 0.05) the plasma triglyceride and cholesterol levels in both male and female rats when compared with the control group (Table 3). Also, ANLA administration increased (P < 0.05) the female rats’ plasma protein concentration, whereas reduced (P < 0.05) plasma triglycerides and cholesterol levels in both male and female rats to near normal levels when compared with the Cr group. ANLA administration in the Cr + A* group did not have any effect (P > 0.05) on the increased plasma cholesterol; however, it significantly (P < 0.05) reduced plasma triglyceride in Cr + A group to normal level when compared with the Cr group (Table 3). Moreover, PDC did not induce any change (P > 0.05) in male liver protein concentration; however, it reduced (P < 0.05) female liver protein concentration while increasing (P < 0.05) hepatic triglyceride and cholesterol levels in both male and female rats when compared with the control group (Table 4). Female rats’ liver protein concentration increased (P < 0.05); however, male hepatic triglycerides and cholesterol levels reduced (P < 0.05) to near normal levels upon ANLA administration when compared with the Cr group. In the female group, ANLA administration reduced (P < 0.05) hepatic triglyceride to a normal level without changing (P > 0.05) the increased hepatic cholesterol level when compared with the Cr group (Table 4). The effect of ANLA on hematological indices in potassium dichromate-induced toxicity in rats is shown in Table 5. Here, PDC increased (P < 0.05) neutrophils, lymphocytes, while basophils, hemoglobin, packed cell volume, and mean corpuscular hemoglobin (Hb) concentration were reduced (P < 0.05) when compared with the control group in both male and female rats. Nevertheless, ANLA treatment reversed (P < 0.05) these anomalies to a normal level when compared with the Cr group. Eosinophils and monocytes were not altered (P > 0.05) by PDC when compared with the control group in both male and female rats. Figure 3 indicates that PDC increased (P < 0.05) chromium concentration in the muscle, intestine, kidney, and liver of both male and female rats compared with the control group. Upon treatment with ANLA, a time-dependent reduction (P < 0.05) of chromium concentration was observed in the organs. In Cr + A group, the male and female kidney chromium concentration, as well as that of the male intestine, were reduced (P < 0.05) to the normal level. The hepatic tissue structure in the control group, as shown in Figure 4A, was regular with a distinct centriole (DC), portal vein (PV), and fenestrated sinusoids (FS). Liver histology in chromium intoxicated group, as shown in Figure 4B, reveals marked cell necrosis (CN), sinusoidal and portal vein dilation with multifocal distortion (MD). The tissue structure in ANLA administered groups depicted improvement compared with the chromium intoxicated group, showing distinct centriole (DC) with mild sinusoidal and portal vein dilation (MSD) (Figure 4C and D).
| Components | Presence |
|---|---|
| Flavonoids | ++ |
| Terpenoids | ++ |
| Saponin | +++ |
| Cardiac glycoside | +++ |
| Tannins | +++ |
| Alkaloids | + |
| Phenol | +++ |
| Anthraquinone | + |
| Constituents | Composition (%) |
|---|---|
| Plant and animal protein | 67.41 ± 2.44 |
| Carbohydrate | 9.87 ± 1.87 |
| Fiber | 10.01 ± 1.21 |
| Fat and oil | 6.63 ± 0.93 |
| Mineral | 6.41 ± 1.08 |
| Variables | Ctrl | Cr | Cr + A* | Cr + A |
|---|---|---|---|---|
| Total Protein (mg/g wet tissue) | ||||
| Male | 2.08 ± 0.22 | 1.98 ± 0.11 | 2.03 ± 0.14 | 2.33 ± 0.13 |
| Female | 3.17 ± 0.58 C | 1.96 ± 0.20 A | 2.79 ± 0.38 B | 2.87 ± 0.42 B |
| Triglycerides (mg/dL) | ||||
| Male | 81.17 ± 9.52 A | 133.79 ± 13.08 C | 103.84 ± 13.85 B | 106.08 ± 15.33 B |
| Female | 86.21 ± 2.80 A | 180.53 ± 13.43 C | 122.72 ± 12.20 B | 84.81 ± 5.77 A |
| Cholesterol (mg/dL) | ||||
| Male | 24.19 ± 6.61 A | 47.18 ± 7.08 C | 34.40 ± 7.43 B | 33.35 ± 6.44 B |
| Female | 41.81 ± 10.11 A | 56.02 ± 9.85 B | 46.31 ± 12.08 B | 50.21 ± 12.89 B |
| Variables | Ctrl | Cr | Cr + A* | Cr + A |
|---|---|---|---|---|
| Total Protein (mg/g wet tissue) | ||||
| Male | 1.91 ± 0.20 | 2.07 ± 0.36 | 1.65 ± 0.18 | 1.85 ± 0.28 |
| Female | 2.26 ± 0.13 B | 1.34 ± 0.14 A | 3.30 ± 0.91 C | 3.76 ± 0.58 C |
| Triglycerides (mg/dL) | ||||
| Male | 94.32 ± 4.76 A | 154.50 ± 12.52 C | 114.19 ± 17.69 B | 137.42 ± 6.25 B |
| Female | 131.757 ± 5.77 A | 307.49 ± 12.44 B | 149.46 ± 5.04 A | 167.09 ± 11.68 A |
| Cholesterol (mg/dL) | ||||
| Male | 16.17 ± 3.51 A | 38.41 ± 8.19 C | 30.68 ± 2.91 B | 30.89 ± 2.74 B |
| Female | 42.83 ± 14.41 A | 66.69 ± 13.07 B | 64.73 ± 12.21 B | 63.35 ± 11.73 B |
| Variables | Ctrl | Cr | Cr + A* | Cr + A |
|---|---|---|---|---|
| Neutrophils (× 109/L) | ||||
| Male | 31.33 ± 0.67 A | 43.00 ± 0.58 B | 29.00 ± 0.77 A | 33.67 ± 0.33 A |
| Female | 31.33 ± 0.66 A | 39.00 ± 0.57 B | 33.67 ± 0.33 A | 28.00 ± 0.82 A |
| Lymphocytes (× 109/L) | ||||
| Male | 41.33 ± 2.76 A | 50.33 ± 1.45 B | 42.67 ± 0.67 A | 41.00 ± 0.85 A |
| Female | 40.67 ± 0.58 A | 57.00 ± 0.77 B | 41.00 ± 0.75 A | 41.00 ± 0.58 A |
| Eosinophils (× 103/mm3) | ||||
| Male | 2.73 ± 1.67 | 2.53 ± 0.88 | 3.17 ± 0.66 | 2.90 ± 0.58 |
| Female | 2.53 ± 0.88 | 1.70 ± 0.66 | 1.90 ± 0.0.57 | 2.10 ± 0.72 |
| Basophils (× 103/mm3) | ||||
| Male | 8.00 ± 1.00 B | 5.00 ± 0.53 A | 5.67 ± 0.77 A | 4.00 ± 0.34 A |
| Female | 8.33 ± 0.67 B | 5.00 ± 0.76 A | 4.00 ± 0.57 A | 4.00 ± 0.58 A |
| Monocytes (%) | ||||
| Male | 2.33 ± 0.33 | 2.00 ± 0.55 | 1.33 ± 0.33 | 2.00 ± 0.57 |
| Female | 3.33 ± 0.67 | 3.00 ± 0.57 | 2.00 ± 0.56 | 3.00 ± 0.41 |
| Hemoglobin (g/dL) | ||||
| Male | 16.80 ± 0.10 B | 11.43 ± 0.13 A | 16.80 ± 0.57 B | 16.53 ± 0.23 |
| Female | 16.30 ± 0.37 B | 12.23 ± 0.39 A | 16.53 ± 0.23 B | 18.00 ± 0.58 B |
| PCV (%) | ||||
| Male | 51.00 ± 0.57 B | 41.00 ± 0.58 A | 48.67 ± 1.00 B | 51.00 ± 0.70 B |
| Female | 47.67 ± 0.33 B | 37.00 ± 0.58 A | 48.67 ± 0.73 B | 51.67 ± 0.34 B |
| MCHC (g/dL) | ||||
| Male | 33.33 ± 0.03 B | 30.60 ± 0.20 A | 33.27 ± 0.33 B | 33.20 ± 0.10 B |
| Female | 33.37 ± 0.20 B | 30.10 ± 0.10 A | 33.20 ± 0.23 B | 33.33 ± 0.08 B |
4. Discussion
Chromium plays a major role in various industrial applications; thus, high industrial pollution of the environment with this metal compound, especially its hexavalent form, is a significant problem (5, 22). This study revealed the potential of A. nilotica leaves to abate K2Cr2O7 induced hepato- and hematotoxicity in male and female experimental animals. Phytocompounds have been linked to various medicinal and pharmacological activities of plants. The presence of these compounds such as flavonoids, terpenoids, phenols, and others, corroborate previous reports (23, 24). Reports on the nutritive value of the leaf are scarce; however, a lot has been done on the pod, fruit, raw, and fermented seeds. The fiber, protein, mineral, fat, and oil contents of ANLA were highly suggestive that ANLA could provide the much-needed energy required rather than other reported leaves (25). Although fiber, mineral, fat, and oil compositions were comparable with other plant parts from previous reports, the protein was way higher. The carbohydrate composition was, however, way lower than other reported plant parts (25-27). Nonetheless, the fiber and mineral values were lower when compared with the seeds from Southern Iran (28). These differences could be attributed to the difference in plant parts and the regions where these plants were located. The liver is the biotransformation site of xenobiotics, making it the major target for toxicants where they can be transformed to less or more toxic intermediates (29). K2Cr2O7 is a hexavalent form of Cr and has been reported to induce toxicity to organs, notably the liver, at various routes and doses (30, 31). Serum enzyme activity is an important pointer for detecting damage to organs and tissues in addition to the severity of the injury. AST and ALT are the common sensitive biomarkers in the serum/plasma used in investigating hepatic function and integrity (32). The uptake of Cr (VI) increased the plasma activities of AST and ALT, while a concomitant decrease of these enzymes in the liver was also observed, indicating hepatic damage. This observation was previously reported in mice, rats, and rabbits (33-35). The increase of these enzyme activities could be as a result of Cr (VI) induced oxidative stress hepatic damage releasing the enzymes from the cytoplasm of hepatocytes into the plasma (36). It was found that after administration of ANLA, these altered activities were normalized, signifying the hepatoprotective ability of ANLA (37). This property could be attributed to the presence of phytochemicals such as flavonoids, terpenoids, and phenols which have been reported to exhibit antioxidant properties (18). They may be involved in mitigating Cr (IV)-induced hepatic damage associated with oxidative stress, as similarly reported by Hfaiedh and colleagues (38). Since hexavalent chromium is a known hepatotoxicant that easily permeates the membrane and accumulates not only in the liver but also other targets, systemic exposure will increase retention in various organs as observed (39). However, antioxidants exert their effect by chelating heavy metals. This might explain the mechanism by which ANLA administration reduced the concentration of chromium in the organs of the rats. These antioxidants may also be associated with the reversed decrease of protein level caused by Cr (IV)-induced toxicity in the female rats (39). It has been demonstrated that ROS generated by Cr (IV) induces tissue and cell damage by disrupting macromolecule arrangement. Also, the high protein content in ANLA is responsible for the synthesis of new protein molecules. The changes in cholesterol and triglycerides levels after Cr (IV) exposure may indicate abnormal lipase enzyme activities, leading to a rise in plasma triglycerides and cholesterol levels. The liver is cholesterol and triglycerides synthesis site, and these abnormalities may be attributed to Cr (IV)-induced hepatic damage via K2Cr2O7 inhibition of triglyceride lipase and unspecific esterase (8). However, when administered with K2Cr2O7, ANLA restores the observed cholesterol and triglycerides modifications, indicating potential hepatoprotective activity agreeing with other reports (33, 40). The blood is a pathological indicator of toxicants effect and other conditions of exposed animals. Hemoglobin concentration in most cases determines red blood cells (RBC) population. In the cause of infection, white blood cells (WBC), including monocytes, granulocytes, and lymphocytes, tend to increase. Thus, the observed WBC increase after PDC administration, suggesting its role as a hemotoxicant. The decrease in Hb and a concomitant decrease in packed cell volume (PCV) and mean corpuscular hemoglobin concentration (MCHC) may be due to disrupting erythropoietin release by PDC or intracellular reduction of Cr (VI) to Cr (III), which then binds subsequently to several intracellular molecules such as hemoglobin. This result agrees with the findings of Balakrishnan et al. (31) and Momo et al. (35). The more tissues retain chromium, the higher tendency for chromium-induced oxidative stress to occur, altering various metabolic pathways in the process of inducing toxicity (22, 37, 41, 42). The ameliorative role of ANLA in reducing tissue retention might be due to its ability to chelate Cr (VI) ion truncating Cr (VI) reduction pathways (43). This may prevent the generation of other Cr ion intermediates implicated in inducing oxidative stress and toxicity (44-46). Chronic administration of ANLA might have reduced liver histology damage by reversing Cr (VI)-altered histoarchitecture of the hepatocytes. These histological changes have been previously reported (30, 39).
4.1. Conclusion
A. nilotica leaves palliated both hepatic and hematologic toxicity associated with chromium intake. It is also a good source of protein and other nutrients. It can also be used for supplementation of animal feed due to its high protein, fiber, mineral, fat, and oil contents. Nonetheless, further studies should be examined for the development of therapeutic products from A. nilotica leaves in abating Cr (VI)-induced systemic damage for occupational exposure population. Moreover, the exact mechanisms by which A. nilotica ameliorates Cr (VI)-induced systemic damage can be further studied.
Acknowledgements
References
-
1.
Permenter MG, Lewis JA, Jackson DA. Exposure to nickel, chromium, or cadmium causes distinct changes in the gene expression patterns of a rat liver derived cell line. PLoS One. 2011;6(11). e27730. doi: 10.1371/journal.pone.0027730. [PubMed: 22110744]. [PubMed Central: PMC3218028].
-
2.
De Flora S, Iltcheva M, Balansky RM. Oral chromium(VI) does not affect the frequency of micronuclei in hematopoietic cells of adult mice and of transplacentally exposed fetuses. Mutat Res. 2006;610(1-2):38-47. doi: 10.1016/j.mrgentox.2006.06.011. [PubMed: 16872865].
-
3.
Ma F, Zhang Z, Jiang J, Hu J. Chromium (VI) potentiates the DNA adducts (O(6)-methylguanine) formation of N-nitrosodimethylamine in rat: implication on carcinogenic risk. Chemosphere. 2015;139:256-9. doi: 10.1016/j.chemosphere.2015.06.077. [PubMed: 26143543].
-
4.
Xia H, Ying S, Feng L, Wang H, Yao C, Li T, et al. Decreased 8-oxoguanine DNA glycosylase 1 (hOGG1) expression and DNA oxidation damage induced by Cr (VI). Chem Biol Interact. 2019;299:44-51. doi: 10.1016/j.cbi.2018.11.019. [PubMed: 30496737].
-
5.
Monteiro J, Cunha LAD, Costa M, Reis HSD, Aguiar A, Oliveira-Bahia VRL, et al. Mutagenic and histopathological effects of hexavalent chromium in tadpoles of Lithobates catesbeianus (Shaw, 1802) (Anura, Ranidae). Ecotoxicol Environ Saf. 2018;163:400-7. doi: 10.1016/j.ecoenv.2018.07.083. [PubMed: 30064085].
-
6.
Barhoma RAE. The role of eugenol in the prevention of chromium-induced acute kidney injury in male albino rats. Alexandria J Med. 2018;54(4):711-5. doi: 10.1016/j.ajme.2018.05.006.
-
7.
Husain N, Mahmood R. 3,4-Dihydroxybenzaldehyde quenches ROS and RNS and protects human blood cells from Cr(VI)-induced cytotoxicity and genotoxicity. Toxicol In Vitro. 2018;50:293-304. doi: 10.1016/j.tiv.2018.04.004. [PubMed: 29665407].
-
8.
Soudani N, Troudi A, Bouaziz H, Ben Amara I, Boudawara T, Zeghal N. Cardioprotective effects of selenium on chromium (VI)-induced toxicity in female rats. Ecotoxicol Environ Saf. 2011;74(3):513-20. doi: 10.1016/j.ecoenv.2010.06.009. [PubMed: 20580087].
-
9.
Barapatre A, Meena AS, Mekala S, Das A, Jha H. In vitro evaluation of antioxidant and cytotoxic activities of lignin fractions extracted from Acacia nilotica. Int J Biol Macromol. 2016;86:443-53. doi: 10.1016/j.ijbiomac.2016.01.109. [PubMed: 26836619].
-
10.
Rather LJ, Mohammad F. Acacia nilotica (L.): A review of its traditional uses, phytochemistry, and pharmacology. Sustain Chem Pharm. 2015;2:12-30. doi: 10.1016/j.scp.2015.08.002.
-
11.
Saratale RG, Saratale GD, Cho SK, Ghodake G, Kadam A, Kumar S, et al. Phyto-fabrication of silver nanoparticles by Acacia nilotica leaves: Investigating their antineoplastic, free radical scavenging potential and application in H2O2 sensing. J Taiwan Inst Chem Eng. 2019;99:239-49. doi: 10.1016/j.jtice.2019.03.003.
-
12.
Sadiq MB, Hanpithakpong W, Tarning J, Anal AK. Screening of phytochemicals and in vitro evaluation of antibacterial and antioxidant activities of leaves, pods and bark extracts of Acacia nilotica (L.) Del. Elsevier. 2017;77:873-82. doi: 10.1016/j.indcrop.2015.09.067.
-
13.
Ali MT, Haque ST, Kabir ML, Rana S, Haque ME. A comparative study of in vitro antimicrobial, antioxidant and cytotoxic activity of Albizia lebbeck and Acacia nilotica stem bark. Bull Fac Pharm Cairo Univ. 2018;56(1):34-8. doi: 10.1016/j.bfopcu.2017.10.002.
-
14.
Saha MR, Dey P, Sarkar I, De Sarker D, Haldar B, Chaudhuri TK, et al. Acacia nilotica leaf improves insulin resistance and hyperglycemia associated acute hepatic injury and nephrotoxicity by improving systemic antioxidant status in diabetic mice. J Ethnopharmacol. 2018;210:275-86. doi: 10.1016/j.jep.2017.08.036. [PubMed: 28859934].
-
15.
Revathi S, Govindarajan RK, Rameshkumar N, Hakkim FL, Al-Buloshi M, Krishnan M, et al. Anti-cancer, anti-microbial and anti-oxidant properties of Acacia nilotica and their chemical profiling. Biocatal Agric Biotechnol. 2017;11:322-9. doi: 10.1016/j.bcab.2017.08.005.
-
16.
Khalid R, Aslam Z, Abbas A, Ahmad W, Ramzan N, Shawabkeh R. Adsorptive potential of Acacia nilotica based adsorbent for chromium(VI) from an aqueous phase. Chin J Chem Eng. 2018;26(3):614-22. doi: 10.1016/j.cjche.2017.08.017.
-
17.
Rani N, Gupta A, Yadav AK. Removal of Cr (VI) from aqueous solutions by Acacia nilotica bark. Environ Technol. 2006;27(6):597-602. doi: 10.1080/09593332708618672. [PubMed: 16865915].
-
18.
Iheagwam FN, Nsedu EI, Kayode KO, Emiloju OC, Ogunlana OO, Chinedu SN. Bioactive screening and in vitro antioxidant assessment of Nauclea latifolia leaf decoction. AIP Conference Proceedings 1954. 2018;1954(1):30015. doi: 10.1063/1.5033395.
-
19.
Elizabeth OO, Nonso IF, Adebola NI, John OJ. Comparative study on chemical composition and antioxidant activity of Annona muricata plant parts cultivated in Covenant University, Ota, Ogun State, Nigeria. Curr Res Nutr Food Sci. 2018;6(3):807-15. doi: 10.12944/crnfsj.6.3.23.
-
20.
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem. 1951;193(1):265-75. doi: 10.1016/s0021-9258(19)52451-6.
-
21.
Kumari K, Khare A, Dange S. The applicability of oxidative stress biomarkers in assessing chromium induced toxicity in the fish Labeo rohita. Biomed Res Int. 2014;2014:782493. doi: 10.1155/2014/782493. [PubMed: 25302308]. [PubMed Central: PMC4180195].
-
22.
Yan J, Huang H, Liu Z, Shen J, Ni J, Han J, et al. Hedgehog signaling pathway regulates hexavalent chromium-induced liver fibrosis by activation of hepatic stellate cells. Toxicol Lett. 2020;320:1-8. doi: 10.1016/j.toxlet.2019.11.017. [PubMed: 31756458].
-
23.
Kalaivani T, Rajasekaran C, Suthindhiran K, Mathew L. Free radical scavenging, cytotoxic and hemolytic activities from leaves of Acacia nilotica (L.) Wild. ex. Delile subsp. indica (Benth.) Brenan. Evid Based Complement Alternat Med. 2011;2011:274741. doi: 10.1093/ecam/neq060. [PubMed: 21799676]. [PubMed Central: PMC3135906].
-
24.
Sharma AK, Kumar A, Yadav SK, Rahal A. Studies on antimicrobial and immunomodulatory effects of hot aqueous extract of Acacia nilotica L. Leaves against common veterinary pathogens. Vet Med Int. 2014;2014:747042. doi: 10.1155/2014/747042. [PubMed: 24804150]. [PubMed Central: PMC3996978].
-
25.
Ndamitso MM, Mustapha S, Etsuyankpa MB, Ajai AI, Mathew JT. Evaluation of chemical composition of Acacia nilotica seeds. FUW Trends in Science & Technology Journal. 2017;2(2):927-31.
-
26.
Ajayi K, Adepoju OT, Taiwo OM, Omojola ST, Aladetuyi ME. Nutritional potential of underutilized gum arabic tree seeds (Acacia nilotica) and locust bean seeds (Parkia biglobosa). Afr J Food Sci. 2018;12(8):196-203. doi: 10.5897/ajfs2017.1650.
-
27.
Bwai MD, Uzama D, Abubakar S, Olajide OO, Ikokoh PP, Magu J. Proximate, elemental, phytochemical and anti-fungal analysis of Acacia nilotica fruit. Pharm Biol Eval. 2015;2(3):52-9.
-
28.
Abbasian K, Asgarpanah J, Ziarati P. Chemical composition profile of Acacia nilotica seed growing wild in south of Iran. Orient J Chem. 2015;31(2):1027-33. doi: 10.13005/ojc/310251.
-
29.
Elshazly MO, Morgan AM, Ali ME, Abdel-Mawla E, Abd El-Rahman SS. The mitigative effect of Raphanus sativus oil on chromium-induced geno- and hepatotoxicity in male rats. J Adv Res. 2016;7(3):413-21. doi: 10.1016/j.jare.2016.02.008. [PubMed: 27222746]. [PubMed Central: PMC4856824].
-
30.
Avila RI, Mattos Alvarenga CB, Avila PH, Moreira RC, Arruda AF, Fernandes TO, et al. Eugenia dysenterica DC. (Myrtaceae) exerts chemopreventive effects against hexavalent chromium-induced damage in vitro and in vivo. Pharm Biol. 2016;54(11):2652-63. doi: 10.1080/13880209.2016.1178306. [PubMed: 27241623].
-
31.
Balakrishnan R, Satish Kumar CS, Rani MU, Srikanth MK, Boobalan G, Reddy AG. An evaluation of the protective role of α-tocopherol on free radical induced hepatotoxicity and nephrotoxicity due to chromium in rats. Indian J Pharmacol. 2013;45(5):490-5. doi: 10.4103/0253-7613.117778. [PubMed: 24130385]. [PubMed Central: PMC3793521].
-
32.
Anandasadagopan SK, Sundaramoorthy C, Pandurangan AK, Nagarajan V, Srinivasan K, Ganapasam S. S-Allyl cysteine alleviates inflammation by modulating the expression of NF-κB during chromium (VI)-induced hepatotoxicity in rats. Hum Exp Toxicol. 2017;36(11):1186-200. doi: 10.1177/0960327116680275. [PubMed: 28988497].
-
33.
Ben Hamida F, Troudi A, Sefi M, Boudawara T, Zeghal N. The protective effect of propylthiouracil against hepatotoxicity induced by chromium in adult mice. Toxicol Ind Health. 2016;32(2):235-45. doi: 10.1177/0748233713498446. [PubMed: 24081637].
-
34.
Saha J, Choudhuri S, Choudhuri D. Effect of sub-chronic exposure to chromium on haematological and biochemical parameters of male albino rat. Asian J Pharm Clin Res. 2017;10(5):345. doi: 10.22159/ajpcr.2017.v10i5.17468.
-
35.
Mary Momo CM, Ferdinand N, Omer Bebe NK, Alexane Marquise MN, Augustave K, Bertin Narcisse V, et al. Oxidative effects of potassium dichromate on biochemical, hematological characteristics, and hormonal levels in rabbit doe (Oryctolagus cuniculus). Vet Sci. 2019;6(1). doi: 10.3390/vetsci6010030. [PubMed: 30889790]. [PubMed Central: PMC6466139].
-
36.
Bayraktar O, Tekin N, Aydin O, Akyuz F, Musmul A, Burukoglu D. Effects of S-allyl cysteine on lung and liver tissue in a rat model of lipopolysaccharide-induced sepsis. Naunyn Schmiedebergs Arch Pharmacol. 2015;388(3):327-35. doi: 10.1007/s00210-014-1076-z. [PubMed: 25480742].
-
37.
Zhao Y, Yan J, Li AP, Zhang ZL, Li ZR, Guo KJ, et al. Bone marrow mesenchymal stem cells could reduce the toxic effects of hexavalent chromium on the liver by decreasing endoplasmic reticulum stress-mediated apoptosis via SIRT1/HIF-1α signaling pathway in rats. Toxicol Lett. 2019;310:31-8. doi: 10.1016/j.toxlet.2019.04.007. [PubMed: 30974164].
-
38.
Hfaiedh M, Brahmi D, Zourgui L. Hepatoprotective effect of Taraxacum officinale leaf extract on sodium dichromate-induced liver injury in rats. Environ Toxicol. 2016;31(3):339-49. doi: 10.1002/tox.22048. [PubMed: 25270677].
-
39.
Zhong X, Zeng M, Bian H, Zhong C, Xiao F. An evaluation of the protective role of vitamin C in reactive oxygen species-induced hepatotoxicity due to hexavalent chromium in vitro and in vivo. J Occup Med Toxicol. 2017;12:15. doi: 10.1186/s12995-017-0161-x. [PubMed: 28638434]. [PubMed Central: PMC5472873].
-
40.
Soudani N, Ben Amara I, Sefi M, Boudawara T, Zeghal N. Effects of selenium on chromium (VI)-induced hepatotoxicity in adult rats. Exp Toxicol Pathol. 2011;63(6):541-8. doi: 10.1016/j.etp.2010.04.005. [PubMed: 20494564].
-
41.
Lv Y, Jiang H, Li S, Han B, Liu Y, Yang D, et al. Sulforaphane prevents chromium-induced lung injury in rats via activation of the Akt/GSK-3β/Fyn pathway. Environ Pollut. 2020;259:113812. doi: 10.1016/j.envpol.2019.113812. [PubMed: 31884211].
-
42.
Yin F, Yan J, Zhao Y, Guo KJ, Zhang ZL, Li AP, et al. Bone marrow mesenchymal stem cells repair Cr (VI)- injured kidney by regulating mitochondria-mediated apoptosis and mitophagy mediated via the MAPK signaling pathway. Ecotoxicol Environ Saf. 2019;176:234-41. doi: 10.1016/j.ecoenv.2019.03.093. [PubMed: 30939403].
-
43.
Pavesi T, Moreira JC. Mechanisms and individuality in chromium toxicity in humans. J Appl Toxicol. 2020;40(9):1183-97. doi: 10.1002/jat.3965. [PubMed: 32166774].
-
44.
DeLoughery Z, Luczak MW, Zhitkovich A. Monitoring Cr intermediates and reactive oxygen species with fluorescent probes during chromate reduction. Chem Res Toxicol. 2014;27(5):843-51. doi: 10.1021/tx500028x. [PubMed: 24646070]. [PubMed Central: PMC4027954].
-
45.
Fang Z, Zhao M, Zhen H, Chen L, Shi P, Huang Z. Genotoxicity of tri- and hexavalent chromium compounds in vivo and their modes of action on DNA damage in vitro. PLoS One. 2014;9(8). e103194. doi: 10.1371/journal.pone.0103194. [PubMed: 25111056]. [PubMed Central: PMC4128586].
-
46.
Wakeman TP, Yang A, Dalal NS, Boohaker RJ, Zeng Q, Ding Q, et al. DNA mismatch repair protein Mlh1 is required for tetravalent chromium intermediate-induced DNA damage. Oncotarget. 2017;8(48):83975-85. doi: 10.18632/oncotarget.20150. [PubMed: 29137397]. [PubMed Central: PMC5663569].